Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug;54 Suppl 4(0 4):44-60.
doi: 10.1111/epi.12298.

Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy

Amy R Brooks-Kayal  1 , Kevin G Bath, Anne T Berg, Aristea S Galanopoulou, Gregory L Holmes, Frances E Jensen, Andres M Kanner, Terence J O'Brien, Vicky H Whittemore, Melodie R Winawer, Manisha Patel, Helen E Scharfman
Affiliations
Review

Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy

Amy R Brooks-Kayal et al. Epilepsia. 2013 Aug.

Abstract

Many symptoms of neurologic or psychiatric illness--such as cognitive impairment, depression, anxiety, attention deficits, and migraine--occur more frequently in people with epilepsy than in the general population. These diverse comorbidities present an underappreciated problem for people with epilepsy and their caregivers because they decrease quality of life, complicate treatment, and increase mortality. In fact, it has been suggested that comorbidities can have a greater effect on quality of life in people with epilepsy than the seizures themselves. There is increasing recognition of the frequency and impact of cognitive and behavioral comorbidities of epilepsy, highlighted in the 2012 Institute of Medicine report on epilepsy. Comorbidities have also been acknowledged, as a National Institutes of Health (NIH) Benchmark area for research in epilepsy. However, relatively little progress has been made in developing new therapies directed specifically at comorbidities. On the other hand, there have been many advances in understanding underlying mechanisms. These advances have made it possible to identify novel targets for therapy and prevention. As part of the International League Against Epilepsy/American Epilepsy Society workshop on preclinical therapy development for epilepsy, our working group considered the current state of understanding related to terminology, models, and strategies for therapy development for the comorbidities of epilepsy. Herein we summarize our findings and suggest ways to accelerate development of new therapies. We also consider important issues to improve research including those related to methodology, nonpharmacologic therapies, biomarkers, and infrastructure.

Keywords: Animal models; Biomarkers; Comorbidity; Epilepsy; Therapy.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adelow C, Andersson T, Ahlbom A, Tomson T. Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy. Neurology. 2012;78:396–401. - PubMed
    1. Aldenkamp AP, Alpherts WC, Dekker MJ, Overweg J. Neuropsychological aspects of learning disabilities in epilepsy. Epilepsia. 1990;31(Suppl 4):S9–S20. - PubMed
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV-TR. 4. American Psychiatric Publishing; Arlington, VA: 2000.
    1. Anisman H, McIntyre DC. Conceptual, spatial, and cue learning in the Morris water maze in fast or slow kindling rats: attention deficit comorbidity. J Neurosci. 2002;22:7809–7817. - PMC - PubMed
    1. Bailet LL, Turk WR. The impact of childhood epilepsy on neurocognitive and behavioral performance: a prospective longitudinal study. Epilepsia. 2000;41:426–431. - PubMed

Publication types

MeSH terms

Substances